DDC Enterprise Expands Bitcoin Holdings to 588 BTC with Latest Acquisition of 100 BTC

bioAffinity Technologies has appointed Roberto Rios and John J. Oppenheimer to its Board of Directors, bringing expertise in corporate finance and clinical leadership. Rios has over 40 years of experience in corporate finance and governance, while Oppenheimer is a leader in asthma and COPD diagnosis and treatment. The appointments will strengthen the company's financial foundation and guide its scientific and clinical strategies.

SAN ANTONIO, July 2, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, has appointed Roberto Rios and John J. Oppenheimer to its Board of Directors. The appointments aim to strengthen the company's financial foundation and guide its scientific and clinical strategies.

Roberto Rios, with over 40 years of experience in corporate finance and governance, brings extensive expertise in financial strategy and risk management to the board. His appointment is expected to bolster bioAffinity's financial stability and support its efforts to expand access to CyPath® Lung, the company's flagship diagnostic tool.

John J. Oppenheimer, a leader in asthma and COPD diagnosis and treatment, will contribute his clinical expertise to bioAffinity's board. His appointment will be instrumental in shaping the company's clinical direction and advancing its next-generation diagnostics and therapeutics.

These appointments come on the heels of bioAffinity's strong second-quarter performance, which saw a 62% year-over-year increase in CyPath® Lung revenues for the six months ended June 30, 2025. The company also reported a 72% increase in CyPath® Lung tests in July, with back-to-back record monthly sales in June and July. The appointment of Dr. Gordon Downie, MD, PhD, as Chief Medical Officer, further underscores bioAffinity's commitment to clinical leadership.

In addition to these appointments, bioAffinity has continued to expand its intellectual property portfolio, with patent grants in the U.S., China, Canada, and Australia. The company also presented novel siRNA-based cancer therapy research at the 2025 RNA Therapeutics Conference, showcasing its innovative approach to selectively kill cancer cells without harming healthy tissue.

Looking ahead, bioAffinity remains focused on expanding access to CyPath® Lung, delivering operational efficiency, and advancing the next generation of diagnostics and therapeutics. The appointments of Rios and Oppenheimer are expected to play a crucial role in achieving these goals.

References:
[1] https://www.businesswire.com/news/home/20250814042365/en/bioAffinity-Technologies-Reports-Second-Quarter-2025-Results